IT1t is a small-molecule antagonist that selectively inhibits the interaction between the CXCR4 chemokine receptor and its ligand CXCL12 (SDF-1α). It is primarily utilized in biomedical research, particularly in studies related to cancer, where it blocks tumor cell migration, invasion, and metastasis by disrupting CXCR4-mediated signaling pathways. These pathways are critical for cell proliferation, survival, and angiogenesis in various cancers. By inhibiting CXCR4, IT1t enables researchers to investigate the mechanisms underlying cancer progression and identify potential therapeutic targets. Additionally, it is used in drug discovery and development to screen and evaluate novel compounds aimed at modulating the CXCR4/CXCL12 axis for targeted cancer therapies, contributing to advancements in personalized medicine.